Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Inclusion Criteria

• •Male and female patients aged ≥12 years from the date of informed consent
• •Confirmed diagnosis of CF at screening
• •Confirmed EPI by historical (within past 12 months) CFA \<70% without use of PERTs or current fecal elastase \<50 µg/g stool at screening
• •Currently receiving PERT with a commercially available pancreatic enzyme
• •Currently on stable treatment with proton pump inhibitors or H2 receptor antagonists
• •Clinically stable condition without evidence of acute respiratory disease or any other acute condition